EditorialTestosterone Deficiency at the Crossroads of Cardiometabolic Complications in CKD
Section snippets
Acknowledgements
I thank my colleagues for never ending support and enthusiasm toward research curiosity.
Support: This editorial was produced without direct funding. Dr Carrero acknowledges grant support from the Swedish Research Council.
Financial Disclosure: Dr Carrero reports having received speaking fees from Bayer Pharmaceuticals (the manufacturer of Nebido) in 2013 and participates in an investigator-driven randomized controlled trial on testosterone replacement therapy in hypogonadal men undergoing
References (36)
- et al.
Serum testosterone levels and mortality in men with CKD stages 3-4
Am J Kidney Dis
(2014) - et al.
Serum testosterone levels and clinical outcomes in male hemodialysis patients
Am J Kidney Dis
(2014) - et al.
Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease
J Ren Nutr
(2013) - et al.
Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescence therapy
Am J Kidney Dis
(1998) - et al.
A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients
Am J Kidney Dis
(1997) - et al.
Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease
Am J Kidney Dis
(1991) - et al.
Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease
Am J Kidney Dis
(2006) - et al.
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM)
J Ren Nutr
(2013) - et al.
Endocrine alterations and cardiovascular risk in CKD: is there a link?
Nefrologia
(2013) - et al.
The vulnerable man: impact of testosterone deficiency on the uraemic phenotype
Nephrol Dial Transplant
(2012)
Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options
J Nephrol
Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD
Clin J Am Soc Nephrol
Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease
Clin J Am Soc Nephrol
Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease
Nephrol Dial Transplant
Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?
Clin J Am Soc Nephrol
Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease
Nephrol Dial Transplant
Cited by (10)
The Other Way Around: Living With Chronic Kidney Disease From the Perspective of Men
2022, Seminars in NephrologyCitation Excerpt :On the one hand, animal studies attribute these differences to deleterious effects of testosterone.21-23 However, this causality is difficult to reconcile with literature regarding the association between testosterone deficiency and adverse clinical outcomes in men with CKD, and the role of testosterone replacement therapy on managing complications of CKD such as anemia or muscle wasting.24,25 Other animal studies have reported that although nitric oxide production is lower in male compared with female animals,26 proinflammatory mediators of kidney injury27,28 and oxidative stress in the kidney are higher.29
Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis
2017, NefrologiaCitation Excerpt :Chronic kidney disease (CKD) involves alterations in body homeostasis and metabolic disturbances (including hormone secretion disorders and altered response to hormones in target tissues), resulting in endocrine dysfunctions that may contribute to the increased mortality in CKD patients.1 Hypogonadism, hallmarked by testosterone deficiency is a common endocrine disorder among men undergoing dialysis, with a prevalence ranging from 35 to 50% in recent studies.2–4 Various studies link hypogonadism with mortality risk among hemodialysis patients,5,6 but the pathways by which this risk may be mediated are not well known.
Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis
2017, NefrologiaCitation Excerpt :Chronic kidney disease (CKD) involves alterations in body homeostasis and metabolic disturbances (including hormone secretion disorders and altered response to hormones in target tissues), resulting in endocrine dysfunctions that may contribute to the increased mortality in CKD patients.1 Hypogonadism, hallmarked by testosterone deficiency is a common endocrine disorder among men undergoing dialysis, with a prevalence ranging from 35 to 50% in recent studies.2–4 Various studies link hypogonadism with mortality risk among hemodialysis patients,5,6 but the pathways by which this risk may be mediated are not well known.
Serum testosterone concentrations and outcomes in hemodialysis patients enrolled in the EVOLVE trial
2023, Nephrology Dialysis TransplantationTestosterone deficiency in male organ transplant recipients
2022, International Journal of Impotence Research